Immunovant, Inc.
Status: Publicly traded
Direct answer
Immunovant, Inc. is publicly traded on NASDAQ under the ticker IMVT.
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in...
Can you invest in Immunovant, Inc.?
Yes. Immunovant, Inc. is publicly traded on NASDAQ under the ticker IMVT.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Immunovant, Inc.
Detailed equity research is provided by MarketSnap.